Perspective Therapeutics Inc (CATX)

$5.65 0.00 (N/A)
Market Cap 420.01M
Revenue (ttm) 1.45M
Net Income (ttm) -79.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,467.59%
Debt to Equity Ratio 0.01
Volume 3,526,600
Avg Vol 3,812,236
Day's Range N/A - N/A
Shares Out 74.34M
Stochastic %K 90%
Beta 1.75
Analysts Strong Sell
Price Target $13.07

Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a bet...

Industry: Medical Devices
Sector: Healthcare
Phone: 206 676 0900
Address:
2401 Elliott Avenue, Suite 320, Seattle, United States
Xanderzzzzzzz
Xanderzzzzzzz Feb. 23 at 2:55 AM
$CATX well said
0 · Reply
GSP
GSP Feb. 23 at 1:47 AM
$ACHC $AXTI $BRLS $BWA $CATX
0 · Reply
The28Investor
The28Investor Feb. 23 at 12:23 AM
$CATX think nows to later to enter?
1 · Reply
RadioIsotope25
RadioIsotope25 Feb. 21 at 10:40 PM
Radiopharm’s imaging molecule hits mark in observational trial for $500 million dollar first of its kind imaging agent- potentially 3rd largest imaging agent in USA- Clinical Trials Arena $RADX $CATX $AKTS $LNTH https://www.clinicaltrialsarena.com/news/radiopharms-imaging-molecule-hits-mark-in-observational-trial/
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 21 at 5:16 PM
$CATX
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 21 at 5:16 PM
$CATX https://www.auntminnie.com/clinical-news/radiation-oncology-therapy/article/15817592/radiopharmaceutical-therapy-use-increased-20fold-over-a-decade
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 21 at 1:03 PM
$CATX
0 · Reply
RadioIsotope25
RadioIsotope25 Feb. 21 at 1:32 AM
Radiopharmaceutical therapy use has increased 2,000% among Medicare population This is good news for this industry $RADX $CATX https://radiologybusiness.com/topics/medical-imaging/nuclear-medicine/radiopharmaceutical-therapy-use-has-increased-2000-among-medicare-population
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 20 at 9:47 PM
$CATX not selling a single share until $18 !!!
4 · Reply
morty104
morty104 Feb. 20 at 9:45 PM
$CATX nice bull flag. Now let’s hoist another….
0 · Reply
Latest News on CATX
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Feb 17, 2026, 7:00 AM EST - 5 days ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Feb 2, 2026, 8:35 AM EST - 20 days ago

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space

Jan 30, 2026, 3:37 PM EST - 23 days ago

Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space

Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 9:46 PM EST - 5 weeks ago

Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Jan 9, 2026, 7:00 AM EST - 6 weeks ago

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:00 AM EST - 2 months ago

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics to Participate in Upcoming December Conferences

Nov 20, 2025, 7:00 AM EST - 3 months ago

Perspective Therapeutics to Participate in Upcoming December Conferences

Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 11:11 PM EST - 3 months ago

Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Nov 10, 2025, 4:05 PM EST - 3 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Perspective Therapeutics to Participate in Upcoming November Conferences

Oct 31, 2025, 7:00 AM EDT - 4 months ago

Perspective Therapeutics to Participate in Upcoming November Conferences

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Oct 24, 2025, 7:00 AM EDT - 4 months ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript

Oct 20, 2025, 5:05 PM EDT - 4 months ago

Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Oct 20, 2025, 4:00 AM EDT - 4 months ago

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Sep 3, 2025, 7:00 AM EDT - 6 months ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Perspective Therapeutics to Participate in Upcoming September Conferences

Aug 26, 2025, 7:00 AM EDT - 6 months ago

Perspective Therapeutics to Participate in Upcoming September Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Aug 13, 2025, 6:45 AM EDT - 6 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Aug 2, 2025, 8:53 AM EDT - 7 months ago

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 24, 2025, 12:45 PM EDT - 7 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jul 15, 2025, 7:00 AM EDT - 7 months ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 8 months ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Jun 21, 2025, 8:00 AM EDT - 8 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 30, 2025, 5:21 PM EDT - 9 months ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 12, 2025, 4:36 PM EDT - 10 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

May 1, 2025, 7:00 AM EDT - 10 months ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 12:25 PM EDT - 10 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 17, 2025, 7:00 AM EDT - 11 months ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Apr 11, 2025, 7:00 AM EDT - 11 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 31, 2025, 7:00 AM EDT - 11 months ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 26, 2025, 4:10 PM EDT - 11 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Mar 13, 2025, 2:52 PM EDT - 1 year ago

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 21, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Feb 5, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 24, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Jan 6, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Dec 23, 2024, 11:13 AM EST - 1 year ago

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Dec 20, 2024, 4:16 PM EST - 1 year ago

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 27, 2024, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 21, 2024, 7:15 AM EST - 1 year ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 15, 2024, 4:08 PM EST - 1 year ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Oct 11, 2024, 12:05 PM EDT - 1 year ago

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 11, 2024, 8:30 AM EDT - 1 year ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 1 year ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Oct 2, 2024, 3:11 PM EDT - 1 year ago

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Xanderzzzzzzz
Xanderzzzzzzz Feb. 23 at 2:55 AM
$CATX well said
0 · Reply
GSP
GSP Feb. 23 at 1:47 AM
$ACHC $AXTI $BRLS $BWA $CATX
0 · Reply
The28Investor
The28Investor Feb. 23 at 12:23 AM
$CATX think nows to later to enter?
1 · Reply
RadioIsotope25
RadioIsotope25 Feb. 21 at 10:40 PM
Radiopharm’s imaging molecule hits mark in observational trial for $500 million dollar first of its kind imaging agent- potentially 3rd largest imaging agent in USA- Clinical Trials Arena $RADX $CATX $AKTS $LNTH https://www.clinicaltrialsarena.com/news/radiopharms-imaging-molecule-hits-mark-in-observational-trial/
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 21 at 5:16 PM
$CATX
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 21 at 5:16 PM
$CATX https://www.auntminnie.com/clinical-news/radiation-oncology-therapy/article/15817592/radiopharmaceutical-therapy-use-increased-20fold-over-a-decade
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 21 at 1:03 PM
$CATX
0 · Reply
RadioIsotope25
RadioIsotope25 Feb. 21 at 1:32 AM
Radiopharmaceutical therapy use has increased 2,000% among Medicare population This is good news for this industry $RADX $CATX https://radiologybusiness.com/topics/medical-imaging/nuclear-medicine/radiopharmaceutical-therapy-use-has-increased-2000-among-medicare-population
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 20 at 9:47 PM
$CATX not selling a single share until $18 !!!
4 · Reply
morty104
morty104 Feb. 20 at 9:45 PM
$CATX nice bull flag. Now let’s hoist another….
0 · Reply
Alacrity2
Alacrity2 Feb. 20 at 9:42 PM
$CATX I am already excited for Monday!
0 · Reply
rughead64
rughead64 Feb. 20 at 9:39 PM
$CATX great week
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 20 at 9:22 PM
$CATX
0 · Reply
ITSALock
ITSALock Feb. 20 at 9:05 PM
$CATX WOW, what a close! Huge accumulation as they play games all day long.
0 · Reply
watchaddict
watchaddict Feb. 20 at 8:20 PM
$CATX Meao0o00o0o0ow
0 · Reply
rughead64
rughead64 Feb. 20 at 8:04 PM
$CATX interested to see if we close strong like the past few days ir stay down a little. Either way it was a solid 4 day week.
0 · Reply
jto2
jto2 Feb. 20 at 7:31 PM
Piper Sandler’s “near-term catalysts” language and $16 PT suggest mid-2026 data may not be as distant as assumed. Support building above VWAP so far. Late shorts could get uncomfortable if this holds. $CATX
0 · Reply
morty104
morty104 Feb. 20 at 6:50 PM
$CATX double push into close? Dare I have hope for a HOD?
1 · Reply
jto2
jto2 Feb. 20 at 6:10 PM
$CATX Perspective Therapeutics’ executives continue to confirm strong hospital demand for Pb-212 — from both patients and physicians. that says everything.
1 · Reply
watchaddict
watchaddict Feb. 20 at 5:45 PM
$CATX cooking after lunch VOL should be interesting
2 · Reply
RadioIsotope25
RadioIsotope25 Feb. 20 at 5:08 PM
Up 85% on Radiopharm imaging data past 90 days $RADX $CATX
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 20 at 5:06 PM
$CATX
0 · Reply